12:00 AM
 | 
Mar 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tamatinib fosdium: Phase II started

Rigel began an open-label, North American Phase II trial to evaluate 200 mg of oral R788 given twice daily for at least 8 weeks or until disease progression. The first stage...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >